Sanofi
Sanofi reported 16 stocks worth $630M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are MGTX (21.3%), INBX (18.4%) and NVAX (11.8%). Compared with Q2 2026, the fund opened new positions in KRSA, ETRA and ATTO.
Latest filing: what Sanofi did in Q3 2026
vs Q2 2026None
None
None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() MGTX Meiragtx Hldgs PLC | $134M | 21.3% | 12.2M | No change | 8 of 8 | |
| 2 | ![]() INBX Inhibrx Biosciences Inc | $116M | 18.4% | 1.2M | No change | 8 of 8 | |
| 3 | ![]() NVAX Novavax Inc | $74.4M | 11.8% | 6.9M | No change | 8 of 8 | |
| 4 | ![]() KRSA Korsana Biosciences Inc | $63.8M | 10.1% | 2M | New position | 1 of 8 | |
| 5 | ![]() ODTX Odyssey Therapeutics, Inc. | $44.2M | 7.0% | 2M | No change | 2 of 8 | |
| 6 | ![]() ANAB Anaptysbio Inc | $41.3M | 6.6% | 822K | No change | 8 of 8 | |
| 7 | ![]() AGMB Agomab Therapeutics NV | $30.9M | 4.9% | 2.8M | No change | 3 of 8 | |
| 8 | ![]() TRAX First Tracks Biotherapeutics | $29.1M | 4.6% | 822K | No change | 2 of 8 | |
| 9 | ![]() ETRA Electra Therapeutics Inc | $27.7M | 4.4% | 2.5M | New position | 1 of 8 | |
| 10 | ![]() ATTO Attovia Therapeutics Inc | $18.6M | 3.0% | 1.1M | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 5, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Sanofi 13F FAQ
What does Sanofi own?
Sanofi reported 16 stocks worth $630M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are MGTX (21.3%), INBX (18.4%) and NVAX (11.8%). The table above lists every position in the filing (the top 10 without an account).
What did Sanofi buy and sell in Q3 2026?
Compared with Q2 2026: 6 new positions, 0 added to, 0 trimmed and 0 sold out. New positions include KRSA, ETRA and ATTO.
When will Sanofi file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Sanofi's portfolio worth?
The Q3 2026 filing reports $630M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.











